

International Journal of Intelligent Enterprise

ISSN online: 1745-3240 - ISSN print: 1745-3232
https://www.inderscience.com/ijie

Unveiling the efficacy of COVID-19 vaccines against emerging SARS-CoV-2 variants

Haldhar Sharma, Ankur Saxena, Sunil Mishra, Mukesh Porwal, Devendra Kumar Pandey

DOI: 10.1504/IJIE.2025.10068127

Article History:

Received:	12 October 2023
Last revised:	12 May 2024
Accepted:	30 July 2024
Published online:	20 December 2024

Unveiling the efficacy of COVID-19 vaccines against emerging SARS-CoV-2 variants

Haldhar Sharma*

Department of Commerce,
Medi-Caps University,
Indore, Madhya Pradesh, India
Email: shaldhar12345@gmail.com
*Corresponding author

Ankur Saxena

Department of Management,
Sanjeev Agrawal Global Educational (SAGE) University,
Bhopal, Madhya Pradesh, India
Email: pro.vc@sageuniversity.edu.in

Sunil Mishra, Mukesh Porwal and Devendra Kumar Pandey

Department of Management Studies,
Medi-Caps University,
Indore, Madhya Pradesh, India
Email: drsunilrmishra@gmail.com
Email: mukeshpor@gmail.com
Email: dkp.567@gmail.com

Abstract: The global coronavirus pandemic has profoundly impacted populations worldwide, leading to widespread illness and mortality. In March 2020, the World Health Organization (WHO) declared the outbreak a global emergency and issued medical guidelines to mitigate the virus's spread. The pharmaceutical industry, educational sectors, and various governments have united in an unprecedented effort to develop and test multiple vaccines swiftly, aiming to control the pandemic and restore global stability. Companies such as Pfizer, Moderna, and GlaxoSmithKline have successfully developed vaccines. However, the SARS-CoV-2 virus mutates, leading to new variants that differ from the original strain, as is typical with viruses. Recent findings indicate that three new coronavirus variants found in several countries may be more severe, evade the immune system better, and show a reduced response to neutralising antibodies. This situation poses a challenge for communicators who must accurately convey the risks and benefits, promote continued caution among vaccinated individuals, and maintain trust in public health measures. Despite the mutations, protection against severe forms of the disease remains robust.

Keywords: concerning SARS-CoV-2; COVID-19 vaccinations; cell-based protection; epidemic coronavirus variants of COVID-19; antibody reactivity; sequencing tracking; vaccine effectiveness.

Reference to this paper should be made as follows: Sharma, H., Saxena, A., Mishra, S., Porwal, M. and Pandey, D.K. (2025) 'Unveiling the efficacy of COVID-19 vaccines against emerging SARS-CoV-2 variants', *Int. J. Intelligent Enterprise*, Vol. 12, No. 1, pp.42–60.

Biographical notes: Haldhar Sharma received his MA and MPhil in Economics from Devi Ahilya University, Indore in 2001 and his PhD from the same university in 2011. He is the HOD of the Department of Commerce at Medi-Caps University, Indore. He has published over 20 research papers and authored a book on 'Economic Co-operation with ASEAN' (2015). He has 16 years of teaching experience and actively conducts research methodology workshops. He has received the best paper presentation award and is a lifetime Madhya Pradesh Economics Association member. His interests include international trade, government policies, and technology and society.

Ankur Saxena, the distinguished Professor and Pro Vice-Chancellor at Sanjeev Agrawal Global Educational (SAGE) University, Bhopal, embodies academic brilliance, leadership, and innovation. With over two decades of service, he has received the 'Excellent Teacher Award' from the M.P. Private University Regulatory Commission and recognition as a 'Notable Personality of Indian Education'. An alumnus of prestigious institutions like IIM Indore, his expertise in entrepreneurship, marketing, and management resonates across academia and industry. His dedication to nurturing talent and fostering academic excellence is unparalleled.

Sunil Mishra is a Professor in Human Resource Management and Organizational Behaviour. He earned his PhD from the Indian Institute of Technology Kharagpur, with his thesis nominated as the 2nd Best Dissertation for Prof. Durganand Sinha's Best Dissertation Award in the XXI Annual Convention of NAOP held at IRMA, Anand in 2011. With 21 years of experience in both industry and academia, Dr. Mishra is actively involved in executive training and management consultancy. He has published numerous research papers, serves on editorial boards of several journals, and is a research supervisor with six scholars under his guidance and two awarded PhDs to his credit. He is also on the Advisory Board of IDAC, the Annual Convention of NAOP, and the Institute of Behavioural and Applied Management.

Mukesh Porwal has been a Professor in the Department of Management Studies at Medicaps University, Indore, India, since September 2017, specialising in IT and marketing. With 25 years of academic and industry experience, he has authored over 35 research papers and four books on digital marketing. He has received various patents and the Best Faculty Award multiple times. He has taught a range of subjects, including IPR, entrepreneurship, and digital marketing, and is a master trainer for Bosch India Foundation. He has also organised numerous seminars and conferences. Before Medicaps, he worked with reputed B-schools like ITS Ghaziabad and MIM Bhopal.

Devendra Kumar Pandey is a techno-commercial professional with an MSc in Applied Chemistry, MBA, PGD-DE, UGC-NET, and PhD. He is a certified Lead Auditor for ISO: 9001 Quality Systems and has approximately 30 years of experience. His leadership roles have included Director – Outcome, Campus Head, HoD, Marketing Manager, Branch Manager, and ISO Lead Manager at institutions like Amity University, ICFAI, Berger Paints, and Modi Industries. He is a Professor in the Faculty of Management at Medi-Caps University, Indore.

1 Introduction

When the COVID-19 epidemic began, researchers collaborated to create more efficient vaccinations than the initial Wuhan variety. Yet, there are some reservations. Concerns have been raised about their efficiency versus SARS-CoV-2 mutations: VOCs mutated in regions identified by eliminating antibodies, allowing them to evade humoral reactions. Research studies evaluating COVID-19 vaccinations against VOCs, on the other hand, have produced excellent protection from severe conditions (Baden et al., 2020). It is a member of the betacoronavirus family, along with the closely related SARS-related and MERSCoV-2 viruses, which cause serious respiratory infections in humans despite their low global frequency and prevalence. Vaccines come in a variety of forms. Whole viral vaccinations contain viruses with genetic material killed by chemical substances, heat, or light. These live attenuated or killed entire viral vaccinations are available (Bernal et al., 2021).

A subunit vaccine is a different sort of vaccine that only comprises clean virus fragments selected for their ability to activate cells of immunity. Against the virus that causes COVID-19, only peptide subunit-based vaccines are being developed. To trigger the immune response, amino acid vaccines exploit the pathogen's genetic components (Braun et al., 2020). In COVID-19, protein spikes on the virus's surface bind to human cells to initiate an immune response. An investigation that projected nAb titer decline found a substantial drop over 225 days, contributing to recurrence (Dan et al., 2022). Outbreaks of illness are also a problem in vaccinated people. Individuals who were given the BNT162b2 mRNA immunisation twice seemed to remain propagation resistant for six months, albeit plasma nAbs then declined (Dugas et al., 2021). In this study, a descriptive and analytical method is used for the assessment. The trend rate of expansion is determined for a total of five nations. The conclusion states that vaccination rates have increased for the inquiry (Abdulsattar et al., 2019). Therefore, there is a functional connection between time and vaccination frequency. The study is dependent on more information (Echeverría et al., 2021). However, both occurrences were exclusively centred on their parent country and were not transmitted to other countries (Garcia-Beltran et al., 2022).

Chatting, choking, inhaling, and snorting are how virus-carrying droplets or particulates from infected people are transferred (Al-Shaeli et al., 2020). The respiratory disease COVID-19 is mostly passed on by particles in the air created by people with the infection, including asymptomatic patients. However, airborne droplets or aerosol transmission has not been verified (Gray et al., 2022). ACE2 receptors can be present in the nervous system, digestion, epithelium, smooth muscle cells in the arteries, and other organs such as the kidneys and liver (Grifoni et al., 2021). As a result, SARS-CoV-2 can produce coagulation deviations, heart impairment, brain symptoms such as regional and local angiogenic events, cerebral or stroke with haemorrhaging, meningoencephalitis, or organ and damage to the liver, alongside respiratory infections (Grifoni et al., 2020).

By assessing the effectiveness of COVID-19 vaccines towards the constantly changing traces of the SARS-CoV-2 virus, this painting fills a sizable vacuum within the literature (Chitra et al., 2024). It does this by concentrating on the implications of nanotechnology and microfibre technologies for vaccine improvement (Ghozali, 2022). Our research broadens the scope to evaluate the reaction of rising variations to more recent vaccination tactics (Gharban et al., 2019). Unlike earlier research, which generally targeted the authentic lines of the virus, emerging variants frequently exhibit alterations

that can elude the immune reaction elicited by using first-technology vaccines (Almanseekanaa et al., 2021).

Our look examines the possibility of higher vaccine transport mechanisms and their efficacy in inducing a strong immune response in opposition to these variations via combining nanotechnology and microfibre technology (Ghozali et al., 2022). Our paintings are new as they offer an intensive review of ultra-modern vaccination technology and its potential to regulate the virus's short genetic adjustments (Ocoró et al., 2023). They supply insightful data on vaccine answers, each scalable and bendy (Ghozali, 2023). Furthermore, the examination contributes greatly to the literature by supplying empirical records on how well those novel technologies functioned in the face of viral evolution, which helped to form plans for vaccine improvement and public health initiatives (Ghozali and Urrohmah, 2023). This research highlights the ability of nanotechnology and microfibre-based vaccines to convert and manage the infectious disorder prevention sector, a primary leap forward in the ongoing worldwide effort to lessen the effect of the COVID-19 pandemic. It also highlights the challenges and possibilities related to their deployment (Kuragayala, 2023).

Those without symptoms had lower levels of harmful cytokines/chemokines than neurotic people. As a result, the virus multiplies quickly in the mouth and causes peeling before symptoms appear (Hoffmann et al., 2022). Given its characteristics, SARS-CoV-2 has a significantly greater viral number than other respiratory viruses (Hurt and Wheatley, 2021; Jongeneelen et al., 2021). In severe COVID-19 instances, lymphocyte hyperactivation, particularly among CD8+ T-cells, results in high insulin levels, Illinois, and tumour necrosis. However, storms of cytokines are caused by fatigue and then accompanied by lymphopenia. At the same time, multiple possibilities for preventing and treating COVID-19 individuals have been proposed. While vaccinations are being developed and used, isolation and separation from society have been proposed to reduce death and disability from COVID-19 (Kundu et al., 2022). Lockdown tactics, on the other hand, have unanticipated consequences. Transportation constraints, clinic shutdowns, and worries about patients at hospital clinics have led to a spike in non-communicable illnesses, and there has been higher mortality and morbidity among kids without vaccines (Le Bert et al., 2020). Economic effects of lockdown tactics exist, particularly in developing countries (Mahajan et al., 2021). As a result, there is a greater need for an effective COVID-19 vaccination (Isa et al., 2023).

The challenge of growing vaccines that stays powerful towards new and evolving infectious diseases offers giant challenges for researchers. Traditional vaccine techniques and the ones using live or killed pathogens, alongside more modern methodologies like vector-based, DNA, peptide, and mRNA vaccines, have all been explored to combat emerging threats (Mateus et al., 2020, 2021). Nanotechnology has emerged as a promising street in recent vaccine development efforts (Mlcochova et al., 2021). This era gives innovative methods to supply vaccine additives, enhancing effectiveness in opposition to hastily mutating viruses like SARS-CoV-2. Despite the benefits, the application of nanotechnology in vaccines faces several hurdles, particularly inside the vicinity of nanoparticle-based total peptide shipping structures (Yturralde and Ramos, 2023). These structures often struggle with stability, transport performance, and ability aspects, which are consequences that must be meticulously addressed to ensure safety and efficacy (Tripathi and Al-Zubaidi, 2023).

Meanwhile, microfibre-primarily-based vaccines constitute another progressive method, cited for their ease of production and scalability. Unlike more complicated nanoparticle structures, microfibre technology allows for the mass production of vaccines, which is crucial throughout a worldwide pandemic (Moderbacher et al., 2020). These microfibre and nanotechnologies are considered present-day healing modalities that significantly enhance medical results. They now provide the possibility to enhance immune responses and achieve this in an unexpectedly tailored manner to counter new editions of viruses as they rise. This dynamic capability is important in the ongoing fight against COVID-19, where the virus's ability to mutate has brought about successive waves of the latest global challenges for public fitness systems.

Knowledge of viruses' genetic and immunogenicity aspects is required to develop vaccines against them (Mok et al., 2021). Given the sudden need and unavailability of effective treatments, researchers have worked relentlessly to create SARS-CoV-2 vaccines. Vaccination techniques have shown promise, including deactivated recombinant, messenger RNA, and nanoparticle-based methods (Montero-Escribano et al., 2020). As a result, we were interested in examining the current vaccine applicants based on presented findings, concentrating on their creation strategy, adverse events, and efficiency, as we were conscious of widespread disinformation regarding COVID-19 and its management, which caused rising sickness death, and expense (Polinski et al., 2022).

The improvement of immunisations, constant hereditary surveillance, and scientific information instruments, all fundamental for following and fighting the infection, has progressed certainly because of the coronavirus plague. Real-time genomic monitoring, which involves sequencing the virus genomes of infected individuals, makes it possible to follow viral evolution and quickly identify novel variants. This technology is supported by global systems like Nextstrain and GISAID, which allow genetic data to be shared globally. The presentation of mRNA antibodies, for example, those delivered by Moderna and Pfizer-BioNTech, has changed immunisation creation by empowering brief antibody updates to battle novel varieties. Moreover, the expectation and control of viral dispersal and the adequacy of inoculations against changes are improved when large information examinations and AI are integrated into general well-being arrangements. Artificial reasoning and robotisation (artificial intelligence) in research facilities improve the capacity and accuracy of testing and sequencing. These are serious areas of strength for ensuring checking and readiness for possible scourges. Combining these specialised developments offers an adaptable design for caring for present and imminent pandemic difficulties.

Our work specialises in the primary problem of the reduced effectiveness of present-day COVID-19 vaccinations towards the SARS-CoV-2 virus's developing traces, which display adjustments that would enable them to circumvent the immune responses produced by preceding vaccinations. It is essential to assess whether the prevailing vaccine technologies employing present-day strategies like nanotechnology and microfibre structures can correctly combat those novel viral lines as they mutate. This looks at the scope purposefully narrowed to evaluate the robustness of those novel vaccination technologies in eliciting an immune reaction that combats and adapts to the virus' genetic permutations. The quickly evolving landscape of viral mutations, which would possibly surpass the duration of our look, and ability boundaries to actual-time global records on vaccination efficacy towards all new editions are many constraints on our studies. The technological preparedness and scalability of state-of-the-art vaccine platforms may not yet be fully realised or available for widespread implementation.

The paper is structured into five main sections. Section 1, the introduction, presents the context and importance of assessing vaccine efficacy against new viral variants. Section 2, the review of literature, synthesises existing research to highlight past findings and gaps in knowledge. Section 3, the methodology of study, details the experimental and analytical methods used to assess vaccine performance. Section 4, results and discussions, presents the data obtained and explores the implications of these findings. Finally, Section 5, the conclusions, summarises the study's key outcomes and suggests directions for future research.

2 Review of literature

Since the dreadful COVID-19 outbreak, humankind has been suffering. On 7 January 2020, Chinese health authorities stated that the cases were related to an entirely novel coronavirus, SAR-CoV-2. The WHO proclaimed the illness a global epidemic on 11 March. Individuals were compelled to don face masks and maintain separation from society, as well as additional measures to control the virus's spread (Sagar et al., 2021). In reaction to this pandemic, the healthcare and academic sectors are collaborating to study and comprehend the biological features of COVID-19 and how to effectively manage it. So far, these investigations have yielded fresh insights into how one gets bitten and how it impacts cells, how the body's immune system responds when fighting the illness, who is at risk of getting infected, and how to evaluate the efficacy and efficacy of various treatment processes.

Second, it is currently unknown if honest sharing of COVID-19 vaccine information would have any expected effect on vaccination rates. On the one hand, as some researchers (Schmidt et al., 2021) propose, understanding clinical trial results and the legal framework may help ease worries over vaccines' effectiveness and safety, hence raising vaccination intention. However, as Montero-Escribano et al. (2020) point out, people may find the material more alarming, which will cause them to believe that vaccines are more dangerous or ineffective. Some might find that the claimed incidence of COVID-19 immunisation side effects is higher than anticipated or that the vaccine's success rate is lower. Studies on the (pre-COVID) vaccination discourse have discovered several effects when good intentions to increase vaccination plans instead lead to safety worries and decrease vaccination desires (Sekine et al., 2020). This has a high morbidity and fatality rate. According to current research, an overall symptom case has a 1.4% risk of being fatal. SARS-CoV-2-induced systemic immune responses of both innate and adaptive types. The first antibody, specific IgM, starts and peaks after one week. As the disorder's acute phase advances, IgM production increases. Specific IgA appears a week after specific IgM, while specific IgG appears nine days after.

The disease stage, which starts with the onset of symptoms and lasts around two weeks, is followed by recovery (Soresina et al., 2020). These diseases can escape the body's natural defence if the immune system cannot resist them, resulting in an intense inflammatory reaction known as cytokine storm (Tan et al., 2021a). Medicines, vaccinations, and therapeutic techniques that affect the mechanisms underpinning immunity are utilised to increase the immune system's fighting capacity. Though numerous state and health agency interventions such as mask use, social distancing, hand washing, and so on may be beneficial in slowing the dissemination of coronavirus

disease, ongoing management requires the creation of a reliable vaccination. Vaccines for COVID-19 with everything slowing or even coming to a standstill, scientists and medical professionals set out to find a long-term alternative to ensure life could resume as usual.

Multi-agency research activities have contributed to the development of vaccines for COVID-19 vaccination. These immunisations protect patients against disease in various ways (Tan et al., 2021b). Due to advances in research, more imaginative vaccine technology equipment, early human trials, and, eventually, strong unity among important bodies 30, the hunt for a vaccine and improved illness detection has moved at an unparalleled velocity. Several vaccinations were created to shield people from the virus's propagation and disastrous effects (Tartof et al., 2021). Preliminary statistics support this assumption, as countries indicate a decrease in transmission rates. When vaccines are limited and at a higher risk of illness, priority is given to health workers and individuals over 65.

Sinovac is suitable for storage in standard refrigerators ranging from 2 to 80 degrees Celsius. In three waves of testing, the vaccine was shown to be 89.12% safe. In Sudan, 93,390 probable cases as of 13 January 2022, and 50,621 verified instances of COVID-19 had been reported to the government's Ministry of Interior (Tseng et al., 2022). The FMOH developed the COVID-19 monitoring at the neighbourhood level initiative. The system was called the 'syndromic approach'.

Residents participated in this initiative to find and identify COVID-19 cases. Each individual was in charge of 150 households, and there were 50 inspections per workday and repeat cycles on the third day. A quick reaction team determining whether those with infections require isolated homes or hospital isolation monitored each group of 40–50 volunteers. Although the vaccination supply is limited, countries must comply with the WHO's establishing objectives guidelines. Roadmap to ensure that vaccinations are given to those who need them the most. As a result, immunisation is recommended for people predisposed to severe COVID-19 caused by concurrent illnesses involving respiratory disorders, the condition, weight and so on. Despite it is known that patients who are female are more likely to catch the disease, data on vaccine safety in this population is sparse (Weiskopf et al., 2020). However, the vaccination is not recommended for anyone with a severe allergic response to any component of the amount being taken.

The two regimens are separated by 28 days. Because the two regimens are comparable, this vaccination, especially the AstraZeneca vaccine, doesn't require booster doses. According to the WHO data, the vaccine's potential benefits outweigh the risks. Countries should follow the WHO Prioritisation RoadMap, as they did with the last immunisation, to prioritise people at higher risk of illness. Including a 95% confidence interval, 196 COVID-19 instances were diagnosed, including 13 cases reported in the vaccine control and 178 in the control category. Compared to the placebo group, the mRNA-1273 immunisation demonstrated a 94.1% effectiveness in suppressing symptomatic SARS-Cov-2 infection. Researchers say this immunisation has no safety risks since only local and systemic responses occur (Yaqinuddin et al., 2021). Individuals with a history of sensitivity to any element of the vaccination or any prior vaccine, as well as those with a severe viral illness, should not receive this vaccine.

2.1 BNT162b2 vaccination from Pfizer

A depicts local reactions. The intensity of pain at the injection location was determined. The intensity of redness and swelling was also assessed. 5B depicts systemic events and pharmaceutical use. There were also scales for weariness, headache, chills, muscular and joint discomfort, vomiting, and diarrhoea. Participants in the placebo group, on the other hand, reported less pain at the injection site. In systemic effects, lethargy was the most common, and vomiting was the least common, regardless of age or dosage. Those who received BNT162b2 had greater rates than those who received a placebo (Zhao et al., 2017). Two shots separated by 21 days.

The vaccination is given through a puncture in the palm of your hand. Anyone over the threshold of 16 is eligible. It is not suggested that those who have had serious adverse reactions to any particular vaccine's ingredients or might get an allergy beyond the first dose receive the immunisation (Kaggle, 2022). Mild to moderate adverse reactions usually occur within seven days of receiving the shot, with only a few persons developing serious symptoms that require hospitalisation or death (Soresina et al., 2020). The financial implications of the pandemic are still being felt. The outlook is still dismal; at the time of writing, it was projected that by 2024, the world economy would have grown by 3.3% less than it would have without the epidemic. Rising costs of commodities, price increases, and debt are some new threats.

Additionally, with another spike in COVID-19 cases anticipated by the end of 2021, the global pandemic still impedes nations' ability to support a complete recovery. The economic damage from the epidemic is compounded by employment inequalities, protectionism, and rising digital, education, and skills disparities, which threaten to split the world into disparate trajectories. Faster vaccine rollout, big digital changes, and new growth prospects in some countries could mean a return to before trends in the near term or a more durable picture over the long run. Many other countries, however, will be held back by low vaccination rates, prolonged extreme strain on medical systems, digital inequalities, and sluggish employment markets.

As nations struggle to control shifting migratory patterns, combat the spread of cyber threats, and deal with the ever-worsening effects of climate change, global cooperation gaps are becoming increasingly severe. Tenacious well-being emergencies like the repetitive spikes in coronavirus variations considerably confuse this developing uniqueness. Astoundingly, cases have been accounted for from regions recently impacted by the infection's initial waves, where the later kinds of SARS-CoV-2 have spread 50–70% more broadly than the first strain. Certain figures show the number of infectious transformations and how powerless recuperated patients are to get a similar sickness once more. The chance of reinfection is particularly troubling because a few assortments are believed to be half more pathogenic than the first, which could risk general well-being frameworks and make the recovery and standardisation process more troublesome.

The intricate connections between these variations can also be seen in their molecular structure and function, which may help to explain why they are more contagious and spreadable. When the infection ties to human cells, compliance changes to more readily focus on an amino corrosive on the phone's external covering. This modification permits the infection to enter cells. Studies have explained this system, which is crucial for the infection's ability to contaminate cells all the more (Hoffmann et al., 2022). A mind-boggling transformation that could help with the infection's spread and effect is demonstrated by the spike protein's linkage to the ORF1b protein, a piece of the

infection's replication hardware. A solitary abandoned RNA genome, estimated around 30 kb long that contains pivotal underlying parts, including an envelope protein and a layered particle, likewise recognises SARS-CoV-2's design. The infection's life cycle and the resistant framework's capacity to distinguish and respond to the disease rely upon these parts (Hurt and Wheatley, 2021; Jongeneelen et al., 2021; Kundu et al., 2022; Le Bert et al., 2020). Understanding these primary components is fundamental to successfully treating and forestalling the infection and laying out general well-being drives that attempt to slow its spread.

These findings have far-reaching repercussions that impact not only public health strategies but also international collaboration on broader issues. The ability to control irresistible sickness pestilences and predict their outcomes becomes progressively significant as the world proceeds to warm and transient examples change in light of various international and natural elements (Mahajan et al., 2021; Mateus et al., 2020, 2021). This situation requires a planned worldwide reaction that integrates well-being security into bigger security and helpful structures to sufficiently deal with the dangers of irresistible infections and their more extensive social ramifications.

Experts cannot identify whether infection outbreaks are caused by increased transmissibility or inadequate infection control efforts. The three variations in this study are classified as variants to be worried about because they share characteristics. Evidence suggests that, when compared to other classifications, these strains are more transmissible and cause severe illness, resulting in decreased immunity and antibody elimination and increased rates of mortality and hospitalisation. Ultimately, they are less useful in examination, therapy, or vaccination because they are created after immunisation or preceding infection. COVID-19 variations' capacity to survive immunisations.

Many governments have launched vaccine campaigns to motivate individuals to obtain vaccine shots to limit the spread of the flu, which still threatens everyone on the planet (Mlcochova et al., 2021). Despite the government's involvement in financing these projects, the programme faces challenges as new types continue to evolve and spread. The emergence of variants has raised various unanswered problems, particularly about their resistance to immunisations (Echeverría et al., 2021). These mutations have developed many S-protein changes, enabling them to go unrecognised or resist both vaccine and natural immune protection. Particular vaccinations are currently prohibited in several jurisdictions. For example, Australia banned AstraZeneca after several of those shot developed blood clots and died (Grifoni et al., 2020). Authorities fear that the US type may be more amenable to the first three vaccinations amid several clinical studies. The influence of the UK strain on vaccine efficacy the E484K mutation in the S-protein in the UK strain is thought to abolish antibody resistance (Dugas et al., 2021).

The influence of the Brazilian strain on vaccine efficacy before the Brazilian strain, the prevalence of respiratory infections was roughly 500 hospitalisations per week on average, as seen in Kundu et al. (2022). Dan et al. (2022) illustrate weekly hospitalisations, whereas 8B depicts weekly cumulative hospitalisation rates. Following a series of studies, an Oxford University research team determined that Pfizer-BioNTech and AstraZeneca vaccines worked towards the Brazilian strain (Le Bert et al., 2020). The study showed that P.1 may be less vulnerable to autoimmune systems and medicines than the other fresh strains after analysing blood specimens from persons who healed from COVID-19 and had spontaneous antibodies. Despite initial concerns that the mutation might reduce vaccine efficacy, the amount of protection remains high. Few investigations have systematically assessed the influence of COVID-19 vaccine data on pertinent views

and actions because no licensed immunisations were available at the point of the investigation. In discrete choice tests, individuals, on average, prefer stronger vaccines with fewer side effects. Nevertheless, clinical research that examined how COVID-19 immunisation affected information about behavioural intentions came up with contradictory findings. For instance, Dugas et al. (2021) use transparent, optimistic comments announcing a safe and effective fake COVID-19 vaccine. Lowered scepticism about immunisations in contrast to ambiguous or unfavourable explicit messaging.

The study, however, did not include a control group, leaving it unclear which interventions affected perceptions compared to a baseline. Furthermore, if such influence exists, vaccine designers and manufacturers are attempting to adapt vaccinations to keep up with the changes. Vaccine manufacturers are working on dose boosters to improve vaccine protection throughout these disparities (Hurt and Wheatley, 2021). A different possibility is to devise a method combining several vaccinations to generate a more potent version capable of combating this disease. Though the pace of studies has been uplifting, there are still difficulties when novel forms of the virus emerge all the time, requiring the vaccine to be modified each time. Because humans are the carriers of these diseases, the concept operates by imbuing select individuals in society with immunity. A small fraction of the populace can be granted immunity in an ignorant population presumed vulnerable to infection. This implies that only a minority will be susceptible, and the condition will spread slowly, reducing incidence rates. There are several new difficulties with SARS-Cov-2, including herd immunity. This strategy has proven ineffective in controlling COVID-19 since the virus is still an emerging illness with unknown characteristics. Furthermore, studies on the consequences of antiviral antibodies have given disappointing results (Mateus et al., 2020).

3 Research methodology

3.1 Objectives of the study

The primary objectives of this study are twofold. Firstly, it aims to analyse the vaccination data on a date-wise basis across selected countries. This will involve collecting and examining the daily vaccine administration records to understand the progression and any specific patterns in the vaccination rollout over time. Secondly, the study seeks to identify and analyse trends in vaccination across these countries. This will include looking at the overall pace of vaccination, identifying periods of acceleration or deceleration, and comparing these trends across different regions to highlight unique strategies or challenges each country faces in their vaccination campaigns.

To study the date-wise vaccination in selected countries: this objective focuses on examining the vaccination data daily within selected countries. By analysing the vaccination records date by date, the study aims to track and understand how the vaccination process unfolds over time in different regions. This detailed examination will help identify specific days or periods with significant vaccination activities, such as launching a new vaccine drive or mass vaccination days. It will also provide insights into the efficiency and responsiveness of the healthcare infrastructure in managing and distributing vaccines to the population.

To study the trend of vaccination in selected countries: the second objective is centred on understanding the broader trends in vaccination across selected countries. This

involves analysing the pace and scale of vaccine distribution and uptake over a longer period. The study will seek to identify patterns such as rapid increases in vaccination rates following policy changes, public health campaigns, or the introduction of new vaccines. It will also compare how different countries' vaccination strategies evolve and how these strategies impact the overall effectiveness of the vaccination campaigns in curbing the spread of the disease.

3.2 Hypotheses of the study

The number of vaccinations in selected countries is increasing over time.

3.3 Methodology

The descriptive and analytical approach is employed for the analysis. There are five countries for the trend growth rate is calculated. According to the findings, vaccination rates have risen during the investigation period. So, a functional relationship exists between time and the number of vaccinations. The research relies on additional information. The information was gathered from (Kaggle, 2022).

For the investigation, a particular formula was used:

3.4 Growth rate of number of vaccinations

During the study duration, a semi-log function was used to calculate the rate of expansion of the total number of COVID-19 vaccinations from 17 January 2021 to 24 July 2021, for Brazil, 28 December 2020 to 23 July 2021, for Germany, 16 January 2021 to 24 July 2021, for India, 14 December 2020 to 23 July 2021, for the UK and 20 December 2020 to 24 July 2021 for USA. The following equation is used to determine growth.

$$\text{Log } Yt = \beta 1 + \beta 2T + Ut$$

Here:

Yt	is the dependent variable (vaccination for COVID-19)
T	period
β1 and β2	regression coefficients
Ut	residual.

A projection of the expansion rate is used to compute the β2 parameter. Using the subsequent formula, the compound rate of growth is determined.

$$\text{Compound growth rate} = (\text{antilog}\,\beta 2 - 1) * 100$$

4 Results and discussion

It is clear from Table 1 that the vaccination rate for COVID-19 is increasing day by day in selected countries. The number of vaccinations on 31 January 2021 was 209,905 for Brazil and 91,839, 306,191, 396,191 and 1,291,416 for Germany, India, the UK and the

USA, respectively. The number of vaccinations increased by 6.62 times, at 1,388,597 for Brazil, 5.09 times at 467,571 for Germany, and 13.15 times at 4,026,626 for India. On the other hand, the number of vaccinations has decreased in the UK and the USA. The number of vaccinations for COVID-19 on 31 January 2021, was 392,361 for the UK; it decreased by 0.55 times and stood at 214,203. The number of vaccinations in the USA was 1,291,416 on 31 January 2021; it decreased by 0.42 times and stood at 537,109 vaccinations on 23 July 2021.

Table 1 Number of vaccinations date-wise (Kaggle, 2022)

Date	*Country name*				
	Brazil	*Germany*	*India*	*UK*	*USA*
31-01-2021	209,905	91,839	306,191	392,361	1,291,416
15-02-2021	241,206	126,405	322,538	422,771	1,662,106
15-03-2021	230,058	258,496	1,419,814	389,942	2,427,430
15-04-2021	1,004,792	531,195	3,269,892	437,318	3,348,189
15-05-2021	800,404	708,886	2,007,240	519,423	1,926,448
15-06-2021	927,995	866,710	3,089,205	458,614	1,137,572
23-07-2021	1,388,597	467,571	4,026,626	214,203	537,109

The number of vaccinations is increasing for Brazil, Germany and India; on the other hand, it is decreasing for the UK and the USA, so it is interesting to study their trend growth rate. It is clear from Table 2 that the growth rate of vaccinations in Brazil is 1.67%, and its R-square is 0.56. The growth rate for Germany is 1.48%, and R-square is 0.86.

Figure 1 Comparative analysis of numerical trends across five countries from January to July 2021 (see online version for colours)



Data from the table are shown in Figure 1, which shows the evolution of numerical values for the USA, Brazil, Germany, India, and the UK across several dates from January to July 2021. Every group of coloured bars represents a different nation and displays the corresponding values for the dates shown on the x-axis. The green line

graph, titled 'country name', combines the data from a single nation and displays an overall rising trend during the time frame. This line graph's values rose sharply in March and April before somewhat declining in July. The line may represent a summary statistic, such as a total or average or the cumulative data for one of the countries across time, without comprehensive legend data. This graphic clearly illustrates the variation and evolution of the data over several months and provides a comparative perspective of the numerical patterns in five different countries.

India's vaccination growth rate is 1.64%, and its R-square is 0.77. The study revealed that the growth rate of vaccination in Brazil, Germany, and India is more than one, and the R-squared rate is above 0.50% over the study period. The growth rate of vaccination in the UK is 0.49, and its R-square is 0.26, which shows that the growth rate is very poor. The growth rate of vaccination in the USA is 0.2%, and R-square is 0.03, which means the growth rate is very poor. The study revealed that the growth rate of vaccination in the UK and the USA is very poor at less than 0.50%. The overall study concludes that our hypothesis is rejected, and an alternate hypothesis is accepted, indicating the vaccination rate has not increased during the research period.

Table 2 Growth rate of vaccination in the top five countries of the world

Country	*Function*	*Year*	*Intercept β1*	*Time β2*	R^2	*Growth rate*
Brazil	Semi log function	17-01-2021 to 24-01-2021	4.98 (0.05) (98.12)	0.01 (0.00) (15.54)	0.56	1.67
Germany	Semi log function	28-12-2020 to 23-07-2021	4.81 (0.02) (226.84)	0.01 (0.00) (36.21)	0.86	1.48
India	Semi log function	16-01-2021 to 24-07-2021	5.51 (0.03) (176.98)	0.01 (0.00) (25.05)	0.77	1.64
UK	Semi log function	14-12-2020 to 23-07-2021	5.27 (0.03) (166.13)	0.00 (0.00) (8.69)	0.26	0.49
USA	Semi log function	20-12-2020 to 24-07-2021	6.00 (0.04) 138.42)	0.00 (0.00) (2.55)	0.03	0.2

Notes: Standard error and t-statistics results are indicated in parenthesis, correspondingly.
t-statistics is significant at a 5% level of significance.

Figure 2, which uses a semi-logarithmic characteristic within predetermined time stages, suggests the 'count of intercept B1 utilising year' for various international locations. The numbers for every US intercept β1 are represented via the vertical bars organised in step with dates. Color-coded and dispersed throughout multiple periods from overdue 2020 to mid-2021 are the USA, Germany, Brazil, India, and the UK. In precise, Germany's bar stands out visibly from the others, indicating a miles better intercept β1 score. Both the graph and the dates' blanks suggest that there's either no information or no dimension for a number of the time intervals. The cause of this visualisation is to evaluate the intercept β1 values over the years and across country-wide borders, giving an outline of the region- and date-specific variations on this unique parameter within the dataset.

Figure 2 Comparative visualisation of intercept β1 values for select countries based on semi-logarithmic analysis (2020–2021) (see online version for colours)



5 Discussions and findings

The data and graphs in the study 'Unveiling the efficacy of COVID-19 vaccines against emerging SARS-CoV-2 variants' provide insight into vaccination trends and growth rates over a predetermined period in five significant nations: Brazil, Germany, India, the UK, and the USA. The continuous appearance of SARS-CoV-2 transformations, which might change the effectiveness of the vaccination, makes this investigation vital. Brazil, Germany, and India showed critical expansions in immunisation rates during the review time frame, as shown by the semi-logarithmic examination, with coefficients demonstrating solid and fast missions. As time passed, the combined number of inoculations expanded consistently, as seen by the positive coefficients (time β2) for Brazil, Germany, and India. This is fundamental to fostering crowd resistance and consequently sluggish the spread of novel and current viral strains.

Then again, the development rates in the USA and the UK were fundamentally lower, with the USA showing a particularly little addition. This can be because of various things, like the immunisation's underlying quick presentation and ensuing immersion of qualified and willing patients, as well as inoculation hesitance, which is a significant impediment. Since a critical part of the designated segment was reached from the beginning, it is conceivable that the lower R-squared values in these nations demonstrate that the number of day-to-day immunisations turned out to be less subject to the slipping time after some time. The viability of immunisation crusades and its adaptability to the pandemic's requests are shown by the useful connections shaped among time and inoculation numbers utilising semi-log capabilities. These examples show the public reaction to vaccination crusades, which is basic considering rising varieties, notwithstanding authoritative and calculated effectiveness. When joined with the known ascent in variation contagiousness and expected escape from resistant assurance, the information showing the extension of absolute immunisations after some time underlines

that adjusting antibody systems to incorporate promoter dosages and fitted immunisations to address variation explicit difficulties is so pressing.

The review's ramifications likewise consider international and financial elements notwithstanding direct general well-being measures. Countries with higher inoculation rates will presumably recuperate monetarily quicker and be stronger to disturbances from new strains. Then again, nations with lower inoculation rates might encounter longer-term general medical problems alongside related monetary hardships. It is clear from a synopsis of these discoveries that worldwide collaboration and information trade are fundamental for further developing inoculation plans and general well-being drives. As evidenced by the variation in immunisation rates and their rise across various regions, a coordinated strategy is required to guarantee equitable vaccine distribution and administration worldwide. This is particularly significant because different variations have various ramifications, which could exacerbate disparity and call for altered mediations given near the study of disease transmission information.

Finally, the study tells an interesting story about how the dynamics of the COVID-19 vaccine rollout interact with the development of virus variants. It is an essential resource for policymakers, public health professionals, and academics to use in developing proactive strategies to prevent problems caused by SARS-CoV-2 variants in the future and reactive to the current pandemic. The findings call for increased international cooperation, flexible vaccine development and administration, and ongoing monitoring to effectively mitigate the pandemic's wider effects.

6 Conclusions

The globe is still recovering from some of the deadliest epidemics ever seen. COVID-19 is a dangerous, persistent respiratory illness that has brought the economy to its knees while simultaneously wreaking havoc on the worldwide medical sector. The virus causes an increase in the rate of exchange, hospitalisation, and fatality. Scientists, health officials, and other nations are all collaborating to combat this disease. This appeared to be under control when various immunisations were developed to protect patients from the disease, including those developed by Moderna, Pfizer, and AstraZeneca. These immunisations had a higher level of efficacy. The increasing reliance on digital technologies, aggravated by COVID-19, has transformed civilisations. Businesses have swiftly transitioned to digitalisation over the past 18 months, people have shifted to part-time employment wherever feasible, and technology and platforms that support this trend have grown. The current investigation found that medical workers globally had an adequate understanding and tolerance of COVID-19 vaccines. The healthcare staff in various sections were usually younger than elsewhere. Like in many other countries, concerns regarding safety and adverse effects governed vaccination acceptance. Most of our survey population believed that healthcare personnel should be the first to be vaccinated, followed by the elderly and persons with chronic diseases. AstraZeneca and Pfizer were the most well-known and widely used COVID-19 vaccine manufacturers. This could be affected by vaccine availability and national vaccine administration policies. The dread of infection for themselves and their family was an encouraging factor for immunization. Currently, there is concern that these strains will diminish the effectiveness of prior vaccinations. Scientists are attempting to learn everything they can about the unique kinds.

A unified method for researching and assessing SARSCoV-2 mutations and their impact on immunisation success is also required. Table 1 indicates that the number of vaccinations is rising in Brazil, Germany, and India while declining in the UK and the USA. The increase in Brazil, Germany, and India suggests effective cooperation between governments and the public, leading to higher vaccination rates. Conversely, vaccination numbers are falling in the UK and the USA, potentially due to widespread resistance. Reports from various news sources suggest that many individuals in these countries are hesitant about getting vaccinated, viewing it as a personal right to refuse the vaccine. Despite earlier studies suggesting an overall increase, the data show varied trends. While vaccination growth rates are above one in Brazil, Germany, and India, indicating robust increases, they are less than one in the UK and the USA, reflecting a decline. This variation rejects the initial hypothesis that vaccination numbers would consistently rise across the selected countries. The results demonstrate that while significant growth has occurred in some nations, others have not seen a substantial increase in vaccination rates over the study period.

References

Abdulsattar, M.S., Ogaili, R.H., Almanseekanaa, L.H. and Ali, A.J.M. (2019) 'Epidemiological analysis of 57 maxillofacial trauma cases', *Biochemical and Cellular Archives*, Vol. 19, No. 2, pp.3159–3164.

Almanseekanaa, L.H., Ali Alabbas, A.K., Kadhim, N.J. and Ogaili, R.H. (2021) 'Molecular study of Pseudomonas aeruginosa isolated from different clinical cases', *Biochemical and Cellular Archives*, Vol. 21, No. 2, p.3079.

Al-Shaeli, S.J., Ethaeb, A.M., and Gharban, H.A. (2020) 'Molecular and histopathological identification of ovine neosporosis (Neospora caninum) in aborted ewes in Iraq', *Veterinary World*, Vol. 13, No. 3, pp.597–603.

Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B.S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J. and Zaks, T. (2020) 'Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine', *New England Journal of Medicine*, Vol. 384, No. 5, pp.403–416.

Bernal, J.L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., Myers, R., Campbell, C.N.J., Amirthalingam, G., Edmunds, M., Zambon, M., Brown, K.E., Hopkins, S., Chand, M. and Ramsay, M. (2021) 'Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant', *New England Journal of Medicine*, Vol. 385, No. 7, pp.585–594.

Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M.A., Beyer, K., Rohmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Gruetzkau, A., Binder, M., Thiel, A., Buchholz, U., Bangert, C., Cornberg, M., Lornitz, S. and Mall, M.A. (2020) 'SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19', *Nature*, Vol. 587, No. 7833, pp.270–274.

Chitra, A., Rajpriya, R. and Karras, D.A., Sridharlakshmi N.R.B., (2024) 'An exhaustive study of parasitic organisms and pathological effects on human health', *AVE Trends in Intelligent Health Letters*, Vol. 1, No. 1, pp.10–18.

Dan, J.M., da Silva Antunes, R., Grifoni, A., Weiskopf, D., Crotty, S. and Sette, A. (2022) 'Observations and perspectives on adaptive immunity to SARS-CoV-2', *Clinical Infectious Diseases*, Vol. 15, No. 75, Suppl 1, pp.S24–S29, https://doi.org/10.1093/cid/ciac310.

Dugas, M., Grote-Westrick, T., Vollenberg, R., Lorentzen, E., Brix, T., Schmidt, H., Tepasse, P-R. and Kühn, J. (2021) 'Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)', *International Journal of Infectious Diseases*, Vol. 105, No. 4, pp.304–306.

Echeverría, G., Guevara, Á., Coloma, J., Ruiz, A.M., Vasquez, M.M., Tejera, E. and de Waard, J.H. (2021) 'Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 interferon-gamma release assay', *International Journal of Infectious Diseases*, Vol. 105, No. 1, pp.21–25.

Garcia-Beltran, W.F., St Denis, K.J., Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L., Berrios, C., Ofoman, O., Chang, C.C., Hauser, B.M., Feldman, J., Gregory, D.J., Poznansky, M.C., Schmidt, A.G., Iafrate, A.J. and Naranbhai, V. (2022) 'mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant', *Cell*, Vol. 185, No. 3, pp.457–466.e4.

Gharban, H.A., Al-Shaeli, S.J., Al-Fattli, H.H., and Altaee, M.N. (2019) 'Molecular and histopathological confirmation of clinically diagnosed lumpy skin disease in cattle, Baghdad Province of Iraq', *Veterinary World*, Vol. 12, No. 11, pp.1826–1832.

Ghozali, M. (2022) 'Mobile app for COVID-19 patient education – Development process using the analysis, design, development, implementation, and evaluation models', *Nonlinear Engineering*, Vol. 11, No. 1, pp.549–557.

Ghozali, M.T. (2023) 'Implementation of the IoT-based technology on patient medication adherence: a comprehensive bibliometric and systematic review', *Journal of Information and Communication Technology*, Vol. 22, No. 4, pp.503–544.

Ghozali, M.T. and Urrohmah, U.A. (2023) 'Determining the relationship between the knowledge on self-management and levels of asthma control among adult asthmatic patients: a cross-sectional study', *Journal of Medicine and Life*, Vol. 16, No. 3, pp.442–446.

Ghozali, M.T., Amalia Islamy, I.D. and Hidayaturrohim, B. (2022) 'Effectiveness of an educational mobile-app intervention in improving the knowledge of COVID-19 preventive measures', *Informatics in Medicine Unlocked*, Vol. 34, No. 10, p.101112.

Gray, G., Collie, S., Goga, A., Garrett, N., Champion, J., Seocharan, I., Bamford, L., Moultrie, H. and Bekker, L-G. (2022) 'Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against Omicron variant in South Africa', *New England Journal of Medicine*, https://doi.org/10.1056/NEJMc2119270.

Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D. and Sette, A. (2021) 'SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19', *Cell Host & Microbe*, Vol. 29, No. 7, pp.1076–1092.

Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., Marrama, D., Krammer, F., Weiskopf, D., Sette, A. and Crotty, S. (2020) 'Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals', *Cell*, Vol. 181, No. 7, pp.1489–1501.e15.

Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A-S., Winkler, M.S., Jäck, H-M., Behrens, G.M.N., Pöhlmann, S. and Wolf, T. (2022) 'The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic', *Cell*, Vol. 185, No. 3, pp.447–456.e11.

Hurt, A.C. and Wheatley, A.K. (2021) 'Neutralizing antibody therapeutics for COVID-19', *Viruses*, Vol. 13, No. 4, p.628.

Isa, I.L.M., Zulkiflee, I., Ogaili, R.H., Yusoff, N.H.M., Sahruddin, N.N., Sapri, S.R. and Mokhtar, S.A. (2023) 'Three-dimensional hydrogel with human Wharton jelly-derived mesenchymal stem cells towards nucleus pulposus niche', *Frontiers in Bioengineering and Biotechnology*, Vol. 11, No. 12, pp.1–9, https://doi.org/10.3389/fbioe.2023.1296531.

Jongeneelen, M., Kaszas, K., Veldman, D., Huizingh, J., van der Vlugt, R., Schouten, T., Zuijdgeest, D., Uil, T., van Roey, G., Guimera, N., Bogers, W.M. and Goudsmit, J. (2021) *Ad26.COV2.S Elicited Neutralizing Activity against Delta and Other SARS-CoV-2 Variants of Concern*, bioRxiv, 2021.2007.2001.450707.

Kaggle (2022) *Kaggle: Your Machine Learning and Data Science Community* [online] https://www.kaggle.com (accessed 10 August 2023).

Kundu, R., Narean, J.S., Wang, L., Fenn, J., Pillay, T., Fernandez, N.D., Conibear, E., Koycheva, A., Davies, M., Tolosa-Wright, M., Tarke, A., Sidney, J., Peters, B., Crotty, S., Weiskopf, D., Grifoni, A. and Sette, A. (2022) 'Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts', *Nature Communications*, Vol. 13, No. 1, p.80.

Kuragayala, P.S. (2023) 'A systematic review on workforce development in healthcare sector: implications in the post-COVID scenario', *FMDB Transactions on Sustainable Technoprise Letters*, Vol. 1, No. 1, pp.36–46.

Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M., Tan, N., Linster, M., Tham, C.Y.L., Bertoletti, A. and Tan, C.C.S. (2020) 'SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls', *Nature*, Vol. 584, No. 7821, pp.457–462.

Mahajan, S., Kode, V., Bhojak, K., Karunakaran, C., Lee, K., Manoharan, M., Ramesh, A., Hv, S., Srivastava, A., Sathian, R., Bose, S. and Das, J. (2021) 'Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals', *Scientific Reports*, Vol. 11, No. 1, p.13164.

Mateus, J., Dan, J.M., Zhang, Z., Moderbacher, C.R., Lammers, M., Goodwin, B., Sette, A., Crotty, S. and Weiskopf, D. (2021) 'Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells', *Science*, Vol. 374, No. 6569, p.eabj9853.

Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S.I., Dan, J.M., Burger, Z.C., Rawlings, S.A., Smith, D.M., Phillips, E. and Weiskopf, D. (2020) 'Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans', *Science*, Vol. 370, No. 6512, pp.89–94.

Mlcochova, P., Kemp, S.A., Dhar, M.S., Papa, G., Meng, B., Ferreira, I.A.T.M., Datir, R., Collier, D.A., Albecka, A., Singh, S., Pandit, R., Govindan, R., Assadi, S., Hasan, M., Mohan, S., Soni, S., Khaleque, H.N., Sundaramoorthy, R., Kumar, D., Hall, N., Peacock, T.P., Brown, J.C., Lythgoe, K.A. and Pybus, O.G. (2021) 'SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion', *Nature*, Vol. 599, No. 7883, pp.114–119.

Moderbacher, C.R., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D., Belanger, S., Abbott, R.K., Kim, C., Choi, J., Crotty, S. and Sette, A. (2020) 'Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity', *Cell*, Vol. 183, No. 4, pp.996–1012.e19.

Mok, C.K.P., Zhu, A., Zhao, J., Lau, E.H.Y., Wang, J., Chen, Z., Zhuang, Z., Wang, Y., Alshukairi, A.N., Baharoon, S.A., Almutawa, M.N., Zhu, A. and Zhao, J. (2021) 'T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study', *The Lancet Infectious Diseases*, Vol. 21, No. 3, pp.385–395.

Montero-Escribano, P., Matías-Guiu, J., Gómez-Iglesias, P., Porta-Etessam, J., Pytel, V. and Matias-Guiu, J.A. (2020) 'Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain', *Multiple Sclerosis and Related Disorders*, Vol. 42, No. 7, p.102185.

Ocoró, M.P., Polo, O.C.C. and Khandare, S. (2023) 'Importance of business financial risk analysis in SMEs according to COVID-19', *FMDB Transactions on Sustainable Management Letters*, Vol. 1, No. 1, pp.12–21.

Polinski, J.M., Weckstein, A.R., Batech, M., Kabelac, C., Kamath, T., Harvey, R., Jain, S., Rassen, J.A., Khan, N. and Schneeweiss, S. (2022) 'Durability of the single-dose Ad26.COV2.S vaccine in the prevention of COVID-19 infections and hospitalizations in the US before and during the Delta variant surge', *JAMA Network Open*, Vol. 5, No. 3, p.e222959.

Sagar, M., Reifler, K., Rossi, M., Miller, N.S., Sinha, P., White, L.F. and Mizgerd, J.P. (2021) 'Recent endemic coronavirus infection is associated with less-severe COVID-19', *Journal of Clinical Investigation*, Vol. 131, No. 1, p.e143380.

Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M. and Nussenzweig, M.C. (2021) 'Plasma neutralization of the SARS-CoV-2 Omicron variant', *New England Journal of Medicine*, Vol. 386, No. 6, pp.599–601.

Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., Wullimann, D.J. and Kämpe, O. (2020) 'Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19', *Cell*, Vol. 183, No. 1, pp.158–168.e14.

Soresina, A., Moratto, D., Chiarini, M., Paolillo, C., Baresi, G., Focà, E., Bezzi, M., Baronio, B., Giacomelli, M. and Badolato, R. (2020) 'Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover', *Pediatric Allergy and Immunology*, Vol. 31, No. 5, pp.565–569.

Tan, C.C.S., Owen, C.J., Tham, C.Y.L., Bertoletti, A., van Dorp, L. and Balloux, F. (2021a) 'Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses', *Infection, Genetics and Evolution*, Vol. 95, No. 11, p.105075.

Tan, H-X., Lee, W.S., Wragg, K.M., Nelson, C., Esterbauer, R., Kelly, H.G., Amarasena, T., Jones, R., Starkey, G., Wang, B.Z., Kent, S.J. and Wheatley, A.K. (2021b) 'Adaptive immunity to human coronaviruses is widespread but low in magnitude', *Clinical and Translational Immunology*, Vol. 10, No. 7, p.e1264.

Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N., Frankland, T.B., Ogun, O.A., Zamparo, J.M., Gray, S., Pan, K. and Angulo, F.J. (2021) 'Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study', *The Lancet*, Vol. 398, No. 10309, pp.1407–1416.

Tripathi, S. and Al-Zubaidi, A. (2023) 'A study within Salalah's higher education institutions on online learning motivation and engagement challenges during COVID-19', *FMDB Transactions on Sustainable Techno Learning*, Vol. 1, No. 1, pp.1–10.

Tseng, H.F., Ackerson, B.K., Luo, Y., Sy, L.S., Talarico, C.A., Tian, Y., Bruxvoort, K.J., Tubert, J.E., Florea, A., Ku, J.H., Lee, G.S., Choi, S.K. and Shen, A.K. (2022) 'Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants', *Nature Medicine*, Vol. 28, No. 5, pp.1063–1071.

Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M., Oja, A.E. and Preiser, W. (2020) 'Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome', *Science Immunology*, Vol. 5, No. 48, p.eabd2071.

Yaqinuddin, A., Shafqat, A., Kashir, J. and Alkattan, K. (2021) 'Effect of SARS-CoV-2 mutations on the efficacy of antibody therapy and response to vaccines', *Vaccines*, Vol. 9, No. 8, p.914.

Yturralde, C. and Ramos, J. (2023) 'A comparative study on work from home during COVID-19: employees perception and experiences', *FMDB Transactions on Sustainable Technoprise Letters*, Vol. 1, No. 4, pp.231–243.

Zhao, J., Alshukairi, A.N., Baharoon, S.A., Ahmed, W.A., Bokhari, A.A., Nehdi, A.M., Layqah, L.A., Alghamdi, M.G., Al Gethamy, M.M., Dada, A.M. et al. (2017) 'Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses', *Science Immunology*, Vol. 2, No. 14, p.eaan5393.